ASCO-SEP® 7th Edition, is a comprehensive resource designed to help providers assess their level of knowledge in the various areas of oncology. This chapter provides a current understanding of lung cancer, its treatment, and the supportive care needed to optimize the quality of life for people with lung cancer.
Immunotherapy continues to improve outcomes in non–small-cell lung cancer (NSCLC). The US Food and Drug Administration (FDA) has approved several chemoimmunotherapy combinations (independent of PD-L1 expression) for patients with advanced NSCLC after demonstrating improvement in overall survival compared with chemotherapy alone. The combination of carboplatin, pemetrexed, and pembrolizumab (Gandhi L, N Engl J Med 2018) and the four-drug regimen of carboplatin, paclitaxel, bevacizumab, and atezolizumab (Socinski M, N Engl J Med 2018) are approved for patients with nonsquamous NSCLC, and carboplatin with paclitaxel or nab-paclitaxel and pembrolizumab is approved for patients with squamous NSCLC. (Paz-Ares L, N Engl J Med 2018)
The addition of the atezolizumab to standard carboplatin plus etoposide for extensive-stage small-cell lung cancer was approved on the basis of an improvement in progression-free survival and overall survival. (Horn L, N Engl J Med 2018)
After definitive chemoradiation for unresectable stage III NSCLC, consolidation therapy with durvalumab led to a significant improvement in overall survival and FDA approval. (Antonia S, N Engl J Med 2018)
Larotrectinib (Drilon A, N Engl J Med 2018) and entrectinib (Paz-Ares L, Ann Oncol 2019) both received tumor-agnostic FDA approval for the treatment of cancers harboring a fusion in NTRK1-3, after demonstrating high response rates across tumor types, including NSCLC.
This site is intended for healthcare professionals in Europe and Japan only.
The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.